Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial

BACKGROUND: Molecular biomarkers including isocitrate dehydrogenase 1 or 2 (IDH1/2) mutation, 1p/19q codeletion, and O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter methylation may improve prognostication and guide treatment decisions for patients with World Health Organization (WHO) anapla...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: Wiestler, Benedikt, Capper, David, Hovestadt, Volker, Sill, Martin, Jones, David T.W., Hartmann, Christian, Felsberg, Joerg, Platten, Michael, Feiden, Wolfgang, Keyvani, Kathy, Pfister, Stefan M., Wiestler, Otmar D., Meyermann, Richard, Reifenberger, Guido, Pietsch, Thorsten, von Deimling, Andreas, Weller, Michael, Wick, Wolfgang
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2014
Soggetti:
Basic and Translational Investigations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4232086/
https://ncbi.nlm.nih.gov/pubmed/25028501
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou138
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi